Aelin Therapeutics

Aelin Therapeutics is a biotherapeutics company based in Belgium, founded in 2017 as a spin-off from VIB.

The company is focused on developing a unique class of peptide-based therapeutics known as Pept-insTM. These therapeutics induce targeted protein aggregation to effectively knock down disease-causing proteins, particularly in the areas of antibiotics and challenging human targets that are difficult to treat. Headquartered in Ghent and Leuven, Aelin Therapeutics has raised $31.86 million in a Series A funding round, attracting investments from notable firms such as PMV, LSP (now EQT Life Sciences), Boehringer Ingelheim Venture Fund, and Fund+. The company's innovative platform aims to address antibiotic resistance by creating new mechanisms that minimize the risk of resistance, paving the way for first-in-class drugs for diseases that are not effectively treated by traditional small molecules or antibodies.